Overview
Raina Patel joined Knobbe in 2021 as an associate in the New York office. Although she focuses primarily on patent prosecution, she also has significant experience in drafting IP transactions, conducting IP due diligence, and assisting on litigation matters. While most of her work is in the medical device space, she also has experience in the food and beverage, fashion, and consumer products industries.
Prior to joining Knobbe, Raina helped develop patent strategies for a wide variety of inventions while working at Boston University’s Office of Technology Development. She also worked with a biotech startup organizing and advancing their patent portfolio.
Education
- Boston University School of Law (J.D., 2021)
- University of Miami (B.S. Biomedical Engineering, 2018), Honors
News & Insights
Articles
Knobbe Martens Litigation Blog
- Co-Author, The Applicant-Action (Or Inaction) Exception (September 8, 2022)
Knobbe Martens Medical Devices & Procedures Blog
- Author, FDA Clears Fasikl’s AI-Powered Felix NeuroAI Wristband for Essential Tremor, (July 8, 2025)
- Author, Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval, (October 21, 2024)
- Author, Johnson & Johnson to Acquire Shockwave Medical in $13.1B Deal, (April 22,2024)
- Author, Updates in the FDA’s Regulation of Digital Health Technologies, (October 27, 2023)
- Author, AI & the FDA, (April 27, 2023)
- Author, Report: Medical Device Market Expected to Grow Over Next Seven Years (November 4, 2022)
- Author, AI and Cancer Diagnostics (September 14, 2022)
Latest Updates and News
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on the skin to deliver alternating electrical fields, termed Tumor Treating Fields (TTFs), thereby disrupting malignant cell division while leaving healthy cells largely unaffected.
Johnson & Johnson to Acquire Shockwave Medical in $13.1B Deal
Johnson & Johnson (J&J) reported on April 5, 2024, that it has entered an agreement to acquire Shockwave Medical, a company in the cardiovascular medical device sector, in a deal totaling a reported $13.1 billion. The deal would further expand J&J into the cardiovascular treatment market.
Updates in the FDA’s Regulation of Digital Health Technologies
The FDA issued a warning letter to Abiomed, for failing to seek approval for its Impella Connect System software before putting it on the market. The Impella Connect System software is designed to work with the company’s Automated Impella Controller (AIC), which is part of a medical device system that provides temporary ventricular support to help a patient’s heart to pump blood in a critical care setting.
Knobbe Martens Team Authors “Recent Developments in Intellectual Property Law 2023” For ABA Business Law Today Section
Knobbe Martens attorneys Julia Hanson, Raina Patel, Nyja Prior, and Mengmeng Du co-authored the article “Recent Developments in Intellectual Property Law 2023” for the ABA’s Business Law Today section. Partner...
AI & the FDA
The use of artificial intelligence (AI) in healthcare has been growing rapidly in recent years, and AI-enabled medical devices are playing a larger role in patient care. Such devices may use machine learning algorithms to analyze vast amounts of patient data and provide diagnoses as well as personalized treatment recommendations. In recent years, the FDA has approved various AI-enabled medical devices, some of which are discussed below.
Report: Medical Device Market Expected to Grow Over Next Seven Years
An article from October 2022 states that the global medical device market is projected to jump by seven billion dollars in 2022 and leap to $223 billion over the next seven years, to reach a valuation of around $719 billion by 2029. A report by consulting firm Fortune Business Insights anticipates a 5.5% compound annual growth rate (CAGR) over this period.
